ABIVAX SA (2X1.DE) Stock Overview
Europe - FRA:2X1 - FR0012333284 - Common Stock
2X1.DE Key Statistics, Chart & Performance
The current stock price of 2X1.DE is 71.9 EUR.
2X1.DE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 4AB.DE | ABBVIE INC | 22.26 | 355.08B | ||
| 1AMGN.MI | AMGEN INC | 13.65 | 136.64B | ||
| AMG.DE | AMGEN INC | 13.64 | 136.47B | ||
| GIS.DE | GILEAD SCIENCES INC | 14.61 | 119.63B | ||
| VX1.DE | VERTEX PHARMACEUTICALS INC | 24.18 | 89.54B | ||
| ARGX.BR | ARGENX SE | 92.61 | 41.71B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 21.65B | ||
| IDP.DE | BIOGEN INC | 9.92 | 19.84B | ||
| 0QF.DE | MODERNA INC | N/A | 9.51B | ||
| 1MRNA.MI | MODERNA INC | N/A | 9.08B | ||
| ABVX.PA | ABIVAX SA | N/A | 6.19B | ||
| 22Z.DE | ZEALAND PHARMA A/S | 5.36 | 3.15B |
Related stock screener links
About 2X1.DE
Company Profile
Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 67 full-time employees. The company went IPO on 2015-06-26. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The firm's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
Company Info
ABIVAX SA
7-11 Boulevard Haussmann
Paris ILE-DE-FRANCE FR
Employees: 67
Phone: 33153830963
ABIVAX SA / 2X1.DE FAQ
What is the stock price of ABIVAX SA today?
The current stock price of 2X1.DE is 71.9 EUR. The price increased by 1.99% in the last trading session.
What is the ticker symbol for ABIVAX SA stock?
The exchange symbol of ABIVAX SA is 2X1 and it is listed on the Deutsche Boerse Ag exchange.
On which exchange is 2X1.DE stock listed?
2X1.DE stock is listed on the Deutsche Boerse Ag exchange.
What is the price forecast or stock price prediction for ABIVAX SA stock?
12 analysts have analysed 2X1.DE and the average price target is 92.27 EUR. This implies a price increase of 28.33% is expected in the next year compared to the current price of 71.9. Check the ABIVAX SA stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ABIVAX SA worth?
ABIVAX SA (2X1.DE) has a market capitalization of 5.57B EUR. This makes 2X1.DE a Mid Cap stock.
How many employees does ABIVAX SA have?
ABIVAX SA (2X1.DE) currently has 67 employees.
What are the support and resistance levels for ABIVAX SA (2X1.DE) stock?
ABIVAX SA (2X1.DE) has a support level at 71.89 and a resistance level at 71.91. Check the full technical report for a detailed analysis of 2X1.DE support and resistance levels.
Is ABIVAX SA (2X1.DE) expected to grow?
The Revenue of ABIVAX SA (2X1.DE) is expected to grow by 87.29% in the next year. Check the estimates tab for more information on the 2X1.DE EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ABIVAX SA (2X1.DE) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of 2X1.DE, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of 2X1.DE, evaluating the profitability, health, valuation and growth aspects
- ABIVAX SA (2X1.DE) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ABIVAX SA (2X1.DE) Sales and EPS estimates to see what analysts future expectations are.
- ABIVAX SA (2X1.DE) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ABIVAX SA (2X1.DE) Insider and Institutional Ownership to learn about the owners and their transactions.
- ABIVAX SA (2X1.DE) Stock Chart to make your own analysis
- ABIVAX SA (2X1.DE) Latest news and press-releases to stay up to date.
Does ABIVAX SA (2X1.DE) stock pay dividends?
2X1.DE does not pay a dividend.
When does ABIVAX SA (2X1.DE) report earnings?
ABIVAX SA (2X1.DE) will report earnings on 2025-12-15.
What is the Price/Earnings (PE) ratio of ABIVAX SA (2X1.DE)?
ABIVAX SA (2X1.DE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.8).
2X1.DE Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to 2X1.DE.
2X1.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to 2X1.DE. 2X1.DE has a bad profitability rating. Also its financial health evaluation is rather negative.
2X1.DE Financial Highlights
Over the last trailing twelve months 2X1.DE reported a non-GAAP Earnings per Share(EPS) of -2.8. The EPS increased by 18.52% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -105.57% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
2X1.DE Forecast & Estimates
12 analysts have analysed 2X1.DE and the average price target is 92.27 EUR. This implies a price increase of 28.33% is expected in the next year compared to the current price of 71.9.
For the next year, analysts expect an EPS growth of 4.58% and a revenue growth 87.29% for 2X1.DE